HERA Invest
European Commission · Venture debt
RollingLast verified 7 Nov 2026
HERA Invest provides venture debt financing via the EIB to innovative European SMEs and mid-caps developing medical countermeasures against priority health threats, such as pandemics, CBRN, and AMR.
Key facts
- Stages
- Seed, Series A, Series B, Series C+
- Sectors
- Biotech & pharma, Healthtech, Defence & security
- Ticket
- €15M–€40M
- Eligible countries
- any EU member state
- Provider based in
- European Union
- Timing
- Rolling applications
- Focus
- Medical countermeasures against priority health threats; Pathogens with pandemic potential and AMR; CBRN threats and dual-use biodefence
- How to apply
- Apply route unknown
Evidence
Short excerpts from the sources, in their original language, that back the facts above.
- Kind
It provides EUR 120m in venture debt financing via the European Investment Bank (EIB)
https://ec.europa.eu/newsroom/hera/redirection/item/926779 - Sectors
developing medical countermeasures (MCMs) against priority threats such as: Pathogens with pandemic potential Chemical, biological, radiological and nuclear…
https://ec.europa.eu/newsroom/hera/redirection/item/926779 - Ticket
Size: EUR 15 to 40m
https://ec.europa.eu/newsroom/hera/redirection/item/926779 - Ticket
Size: EUR 15 to 40m
https://ec.europa.eu/newsroom/hera/redirection/item/926779
Status history
- 6 Nov 2026: Rolling (first extraction)
Something wrong or out of date? Report an error.